ERBB2 and neoplasm: Our research provides a comprehensive understanding of how HER2 amplicon expression is activated in HNMT-overexpressing cells, shedding light on the molecular basis for the distinctive H-cell phenotype observed in the tumor tissues of individuals responding to trastuzumab treatment.